Format

Send to

Choose Destination
Lung Cancer. 2017 Jun;108:109-114. doi: 10.1016/j.lungcan.2017.03.010. Epub 2017 Mar 24.

Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib.

Author information

1
Departments of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, United States.
2
Departments of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, United States.
3
Departments of Thoracic Oncology, Memorial Sloan Kettering Cancer Center, New York, United States.
4
Departments of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, United States. Electronic address: wua@mskcc.org.

Abstract

OBJECTIVES:

Patients with metastatic EGFR-mutant (mEGFRmt) NSCLC have favorable survival when treated with erlotinib. We hypothesized that treatment failure in most patients is limited to initial sites of disease, in which case incorporating local therapy such as radiation might further delay progression. We therefore analyzed patterns and predictors of failure in a large cohort of such patients.

MATERIALS AND METHODS:

We reviewed 189 patients treated with erlotinib for mEGFRmt NSCLC. We classified first pattern of failure as involving initial sites only (ISF), new sites only (NSF), or the combination (CSF), and used competing-risks regression to identify factors associated with ISF, progression and overall survival (OS). We also separately analyzed intracranial and intrathoracic failure.

RESULTS:

Of 171 patients who progressed, 103 (60.2%) had ISF, 30 (17.5%) had NSF, and 38 (22.2%) had CSF. Younger age and lack of initial CNS involvement independently correlated with ISF, with a trend for higher T and N stage. Higher T and N stage was also a significant predictor of progression. Factors predicting shorter OS were female gender, weight loss, initial intracranial involvement, and ≥4 extracranial metastases. Intrathoracic progression was a component of first failure in 61%, and three-year cumulative incidence of brain metastasis was 30%.

CONCLUSION:

The main pattern of progression in mEGFRmt NSCLC on erlotinib is in the initial sites of disease. Younger patients and those without brain involvement are particularly likely to develop ISF. This suggests a role for incorporating local therapy into treatment of selected patients with mEGFRmt NSCLC.

KEYWORDS:

CNS; EGFR; Erlotinib; NSCLC; Oligometastatic

PMID:
28625621
PMCID:
PMC5477661
DOI:
10.1016/j.lungcan.2017.03.010
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center